New drug combination could delay cancer

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleNew research has found that a combination of drugs, including niraparib, could delay the advancement of a deadly form of prostate cancer.The study, involving 696 men across 32 countries, showed the new drug combination reduced the risk of cancer growth by 37 per cent overall, and by 48 per cent in a subgroup of patients with specific genetic mutations. Medics also observed that the time until symptoms worsened was twice as long for patients receiving niraparib, decreasing the number of patients with notable symptom worsening from 34 per cent to 16 per cent. Professor Gerhardt Attard, who led the study, emphasised the need for widespread genomic testing to identify patients with homologous recombination repair (HRR) gene mutations who would benefit most. Niraparib is currently approved in the UK for treating some types of cancer, but has not yet received approval for prostate cancer. In full‘Striking’ new treatment for deadly prostate cancer could increase life expectancyThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata daindependent.co.uk